基本信息
浏览量:2
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
The major area of my research focus is in the evaluation of new agents and approaches in phase I, pilot and early phase II trials. This includes the evaluation of pharmacokinetics and biological correlates of the activity of these agents or approaches. As an example, for the past 5 years, I have been working on evaluation of crizotinib as an ALK, ROS1, and MET inhibitor. I am also especially interested in the development of new theraputic approaches for gastrointestestional malignancies. I have an interest in designing and implementing systems to improve the quality and performance of clinical trials. This includes the development and utlization of computerized systems whenever possible. This involves close collaboration with a large group of individuals involved in the clinical research process.
研究兴趣
论文共 389 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Journal of computer assisted tomographyno. 4 (2024): 628-639
Brandon M. Huffman,Harshabad Singh,Lestat R. Ali,Nora Horick,S. Jennifer Wang,Megan T. Hoffman, Katherine A. Metayer, Shayla Murray, Alexandra Bird,Thomas A. Abrams,Leah H. Biller,Jennifer A. Chan,
crossref(2024)
Investigational New Drugsno. 2 (2024): 221-228
Journal of computer assisted tomographyno. 4 (2024): 614-627
crossref(2023)
ONCOLOGISTno. 4 (2023): 341-350
Harshabad Singh,Samuel J. Klempner,Nelya Melnitchouk, Deepak P. Chander, Ovidiu George Negrea,Anuj K. Patel,Benjamin L. Schlechter,Douglas A. Rubinson,Brandon M. Huffman,Chetan Nambiar,Joshua Remland,Elizabeth Andrews,
JCO PRECISION ONCOLOGYno. 7 (2023): e2200572-e2200572
crossref(2023)
Clinical PET/MRIpp.333-364, (2023)
加载更多
作者统计
#Papers: 393
#Citation: 36725
H-Index: 79
G-Index: 189
Sociability: 8
Diversity: 3
Activity: 138
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn